KPTI Karyopharm Therapeutics Inc
Price (delayed)
$4.06
Market cap
$34.17M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$9.45
Enterprise value
$165.88M
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related
Highlights
The EPS has grown by 50% YoY and by 20% from the previous quarter
The net income has grown by 47% YoY and by 13% from the previous quarter
Karyopharm Therapeutics's quick ratio has plunged by 52% YoY and by 43% from the previous quarter
The equity has contracted by 37% YoY and by 17% from the previous quarter
Key stats
What are the main financial stats of KPTI
Market
Valuations
Earnings
Shares outstanding
8.42M
Market cap
$34.17M
Enterprise value
$165.88M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.14
Revenue
$145.24M
Gross profit
$139.23M
Operating income
-$119.44M
Net income
-$76.42M
EBIT
-$38.94M
EBITDA
-$38.6M
Free cash flow
-$127.63M
Per share
Balance sheet
Liquidity
EPS
-$9.45
EPS diluted
-$13.95
Free cash flow per share
-$15.71
Book value per share
-$22.27
Revenue per share
$17.88
TBVPS
$20.24
Total assets
$164.42M
Total liabilities
$350.44M
Debt
$194.52M
Equity
-$186.02M
Working capital
$64.23M
Debt to equity
-1.05
Current ratio
1.7
Quick ratio
1.52
Net debt/EBITDA
-3.41
Margins
Efficiency
Dividend
EBITDA margin
-26.6%
Gross margin
95.9%
Net margin
-52.6%
Operating margin
-82.2%
Return on assets
-39.6%
Return on equity
N/A
Return on invested capital
-15.5%
Return on capital employed
-54%
Return on sales
-26.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KPTI stock price
How has the Karyopharm Therapeutics stock price performed over time
Intraday
14.69%
1 week
-16.29%
1 month
-48.93%
1 year
-80.59%
YTD
-59.96%
QTD
8.56%
Financial performance
How have Karyopharm Therapeutics's revenue and profit performed over time
Revenue
$145.24M
Gross profit
$139.23M
Operating income
-$119.44M
Net income
-$76.42M
Gross margin
95.9%
Net margin
-52.6%
The net income has grown by 47% YoY and by 13% from the previous quarter
KPTI's net margin is up by 46% YoY and by 11% from the previous quarter
KPTI's operating income is up by 8% YoY and by 5% QoQ
KPTI's operating margin is up by 7% YoY and by 3.2% QoQ
Growth
What is Karyopharm Therapeutics's growth rate over time
Valuation
What is Karyopharm Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
0.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.14
The EPS has grown by 50% YoY and by 20% from the previous quarter
The equity has contracted by 37% YoY and by 17% from the previous quarter
The P/S is 95% lower than the 5-year quarterly average of 4.0 and 75% lower than the last 4 quarters average of 0.8
The revenue has contracted by 2.2% from the previous quarter
Efficiency
How efficient is Karyopharm Therapeutics business performance
The ROS has soared by 67% YoY and by 27% from the previous quarter
Karyopharm Therapeutics's return on invested capital has surged by 57% YoY and by 23% QoQ
KPTI's ROA is up by 22% YoY and by 3.9% QoQ
Dividends
What is KPTI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KPTI.
Financial health
How did Karyopharm Therapeutics financials performed over time
KPTI's total assets is 53% smaller than its total liabilities
Karyopharm Therapeutics's quick ratio has plunged by 52% YoY and by 43% from the previous quarter
The current ratio has contracted by 50% YoY and by 43% from the previous quarter
The equity has contracted by 37% YoY and by 17% from the previous quarter
KPTI's debt to equity is up by 19% year-on-year and by 14% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.